Lack of any Association between Blood Groups and Lung Cancer, Independent of Histology

Abstract

Introduction: Lung cancer, the leading cause of cancer deaths, is divided into 2 main classes based on its biology, therapy and prognosis: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Many cases are at an advanced stage at diagnosis, which is a major obstacle to improving outcomes. It is important to define the high risk group patients for early diagnosis and chance of cure. Blood group antigens are chemical components on erythrocyte membranes but they are also expressed on a variety of epithelial cells. Links between ABO blood groups with benign or malignant diseases, such as gastric and pancreas cancers, have been observed for a long time. In this study, we aimed to investigate any possible relationship between lung cancer histological subtypes and ABO-Rh blood groups. Materials and Methods: The files of 307 pathologically confirmed lung cancer patients were reviewed retrospectively. Cases with a serologically determined blood group and Rh factor were included and those with a history of another primary cancer were excluded, leaving a total of 221. The distribution of blood groups of the lung cancer patients were compared with the distribution of blood groups of healthy donors admitted to the Turkish Red Crescent Blood Service in our city in the year 2012. Results: There was no significant difference between patients with lung cancer of either type and the control group in terms of distribution of ABO blood groups and Rh factor (p: 0.073). There was also no relationship with non small cell cancer histological subtypes. Conclusions: In this study, we found no relationship between the ABO-Rhesus blood groups and NSCLC and SCLC groups. To our knowledge this is the first analysis of ABO blood groups in SCLC patients.

Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer

“…These alterations are hypothesized to be important for the development of certain malignancies (26,27). However, data concerning the role of ABO blood groups in lung cancer are limited and inconsistent (28)(29)(30). In the present study, no significant difference was observed between patients with lung cancer and healthy controls in terms of the distribution of ABO blood types, which is similar to the study by Oguz et al (28), but different from that of Urun et al (29), who identified an association between non-O blood types and an increased risk of lung cancer.…”

Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination

“…Clinical and pathological research found that lung cancer is heterogeneous (Oguz et al, 2013). To improve the diagnostic sensitivity and specificity, severed tumor markers, combined together could be more effective in the diagnosis of lung cancer.…”

Serum IL-33 as a Diagnostic and Prognostic Marker in Non-small Cell Lung Cancer

“…Non-small cell lung cancer (NSCLC) is the main type of lung cancer. NSCLC is often diagnosed at an advanced stage (Oguz,et al, 2013) so that patients have little prospect of effective and curative treatment, with 5-year survival rates of < 15% (Jemal et al, 2010).…”